Search Results

Welldoc Receives 10th 510(k) Clearance from FDA for Award-Winning Diabetes Platform BlueStar.

Welldoc®, a digital health leader revolutionizing chronic care, today announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar®.

Welldoc Granted 31st Patent for First-in-Class Chronic Care Platform.

CCS has announced a new technology partnership Welldoc and ZeOmega to expand its established LivingConnected® solution.

Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development.

Welldoc, a trailblazer in digital health that is revolutionizing chronic condition management, and Dexcom, the leader in real-time continuous glucose monitoring (CGM), today announced the first customer for a new integrated offering to drive improved health for people with Type 2 diabetes. Welldoc will offer its BlueStar ® digital health

Welldoc, announced today a collaboration with Dexcom, the global leader in continuous glucose monitoring (CGM) systems for people with diabetes.

Validic, and Welldoc announced their partnership to broaden the access and integration of personal health data within the Welldoc BlueStar® platform.

Feb. 25, 2020 14:00 UTC Welldoc and Redox Partner to Optimize Provider Interaction with Chronic Disease Management Platform Partnership ensures bidirectional integration with EHRs and insights available at the point of care MADISON, Wis.--( BUSINESS WIRE )-- Welldoc , a leading digital health company revolutionizing chronic disease management, announced today its strategic partnership with Redox Inc. , the leading interoperability platform for healthcare data exchange.

This is Welldoc’s 8th 510(k) filing to the U.S. Food and Drug Administration